4528:TYO
오노약품공업
JP¥2,334.00
arrow_downward
-0.95%(-22.50) 1D
4월 22일, 오전 11시 30분 0초 GMT+9 · JPY
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto4528의 주요 통계 생성 중...
시가
JP¥2,342
고가
JP¥2,345
저가
JP¥2,304
시가총액
1.16조
평균 거래량
203.07만
거래량
77.33만
배당금
3.43%
분기 배당금
JP¥20
배당락일
2025. 9. 29.
주가수익률
17.58
52주 최고가
JP¥2,674
52주 최저가
JP¥1,474
EPS
JP¥133
유통 주식수
5.14억
직원 수
4천
뉴스 기사
웹 소스 기반
MarketBeat
·
1시간 전
Photronics (NASDAQ:PLAB) CAO Sells $212,765.20 in Stock
스페셜경제
·
3시간 전
뉴욕증시, 이란 협상 불확실성에 약세…다우 300P↓
블루밍비트
·
4시간 전
[뉴욕증시 브리핑] 미·이란 2차협상 경계감에 하락…S&P500 0.6%↓
프로필
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
오노약품공업에 관한 정보